Analysis of recent trends in prostate cancer incidence and mortality

Prostate

Volumn 42, Issue 4, 2000, Pages 247-252

  Dennis, Leslie K ^a   Resnick, Martin I ^b  

^a UNIVERSITY OF IOWA   (United States)

^b CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Bias; Incidence; Mass screening; Prostatic neoplasms; Registries; SEER Program

Indexed keywords

ARTICLE; CANCER DIAGNOSIS; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER REGISTRY; CANCER SCREENING; CANCER STAGING; HUMAN; MALE; PRIORITY JOURNAL; PROSTATE CANCER;

HUMANS; INCIDENCE; MALE; MORTALITY; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REGISTRIES; UNITED STATES;

EID: 0033965424     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0045(20000301)42:4<247::AID-PROS1>3.0.CO;2-5     Document Type: Article

References (16)

1. Landis SH, Murray T, Boldon S, Wingo PA. Cancer statistics, 1999. CA Cancer J Clin 1999;49:8-31.
2. Dennis LK. An analysis of the melanoma epidemic both apparent and real: based on the 1973-1994 SEER registry. Arch Dermatol 1999;135:275-280.
3. National Cancer Institute, Division of Cancer Prevention and Control, Surveillance Program, Cancer Statistics Branch. Surveillance, Epidemiology, and End Results (SEER) Program public use CD-ROM (1973-1996). Bethesda, MD: National Cancer Institute; 1999.
4. Percy C, Van Holten V, Muir C, eds. World Health Organization. International classification of diseases for oncology, 2nd ed. Geneva: World Health Organization; 1990. p 15.
5. Breslow NE, Day NE. Statistical methods in cancer research, volume 1: the analysis of case-control studies. Lyon: International Agency for Cancer Research; 1980. p 131-136.
6. Swerlick RA, Chen S. The melanoma epidemic: more apparent than real? Mayo Clin Proc 1997;72:559-564.
7. Gordis L. Epidemiology. Philadelphia: W.B. Saunders Co.; 1996. p 235-238.
8. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, Petros JA, Andriole GL. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 1991;324:1156-1161.
9. Williams RB, Boles M, Johnson RE. Use of prostate specific antigen for prostate cancer screening in primary care practice. Arch Fam Med 1995;5:311-315.
10. Akazaki K, Stemmerman GN. Comparative study of latent carcinoma of the prostate among Japanese in Japan and Hawaii. J Natl Cancer Inst 1973;50:1137-1144.
11. Breslow N, Chan CW, Dhom G, Drury RAB, Franks LM, Gellei B, Lee S, Lundberg S, Sparke B, Sternby NH, Tulinius H. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer 1977;20:680-688.
12. Guileyardo JM, Johnson WD, Welsh RA, Akazaki K, Correa P. Prevalence of latent prostate carcinoma in two US populations. J Natl Cancer Inst 1980;65:311-316.
13. Coffield KS, Speights VO, Brawn PN, Riggs MW. Ultrasound detection of prostate cancer in postmortem specimens with histological correlation. J Urol 1992;147:822-826.
14. Stemmerman GN, Nomura AM, Chyou PH, Yatani R. A prospective comparison of prostate cancer at autopsy and as a clinical event: the Hawaii Japanese experience. Cancer Epidemiol Biomark Prev 1992;1:189-193.
15. Kramer BS, Brown MI, Prorok PC, Potosky AL, Gohagan JK. Prostate cancer screening: what we know and what we need to know. Ann Intern Med 1993;119:914-923.
16. Pollack HM, Resnick MI. Prostate-specific antigen and screening for prostate cancer: much ado about something? Radiology 1993;189:353-356.